Polpharma Biologics S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2018-12-31
Share capital
1,175,432,600.00 PLN
Activity description

Polpharma Biologics is a biotechnology company that specializes in the development and manufacturing of biosimilars and innovative biologics. They provide customized CDMO services, taking biosimilars from concept to clinical trials and supporting global commercial supply. The company collaborates with major biopharmaceutical partners to enhance patient access to high-quality alternatives for various diseases.

Registered address
ul. Trzy Lipy 3, 80-172 Gdańsk, Poland
Email
Social media
Electronic delivery address
AE:PL-37878-93960-EAVTH-17

Financials

Revenue history (in m)

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 105 days for 2023). All were audited by a statutory auditor.

  • 202531/07/2026
  • 202402/07/2025
  • 202328/10/2024
  • 202227/06/2023
  • 202104/07/2022
  • 202003/08/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top <1%
City · Gdańsk16 / 7,502
Top <1%
Voivodeship · Pomorskie33 / 20,062
Top <1%
Country · Poland690 / 297,069
Top <1%

Results vs industry

Revenue
This companyUSD 311.66mMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD 141.77mMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 262.41mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 474.91mMedianUSD 281.58kAverageUSD 8.35m

News

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate

Rotkreuz – 31 July 2026 – Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately…

Teva and Polpharma Biologics Announce Global Licensing Agreement for A Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Teva and Polpharma Biologics Announce Global Licensing Agreement for A Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

TEL AVIV, ISRAEL, and Zug, Switzerland July 9, 2026 (GLOBE NEWSWIRE) – Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus® 1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma…

Polpharma Biologics and PSI CRO Collaborate on Phase 1 Biosimilar Study in Multiple Sclerosis

Polpharma Biologics and PSI CRO Collaborate on Phase 1 Biosimilar Study in Multiple Sclerosis

June 03, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development of biosimilars, announced a collaboration with PSI CRO for the execution of a Phase 1 clinical study evaluating PB018, a proposed biosimilar to Ocrevus® (ocrelizumab), in patients with Multiple Sclerosis (MS).

Polpharma Biologics and Tuteur sign a licensing agreement for a biosimilar targeting autoimmune diseases

Polpharma Biologics and Tuteur sign a licensing agreement for a biosimilar targeting autoimmune diseases

May 22, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur . Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the…

Bioeq and Zydus partner on U.S. commercialisation rights for NUFYMCO®, an interchangeable biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA

Bioeq and Zydus partner on U.S. commercialisation rights for NUFYMCO®, an interchangeable biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA

December 23, 2025 –Polpharma Biologics is pleased to acknowledge the recent announcement of Bioeq AG, our joint venture, regarding the licensing, supply, and commercialization agreement with Zydus Lifesciences Ltd. for NUFYMCO® (biosimilar ranibizumab), an interchangeable biosimilar to Lucentis®, in the United States.

Polpharma Biologics and Libbs Farmacêutica sign licensing agreement for a biosimilar for autoimmune diseases

Polpharma Biologics and Libbs Farmacêutica sign licensing agreement for a biosimilar for autoimmune diseases

December 10, 2025 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market.

Offer

  • Biosimilar drug development
  • Biosimilar drug development services
  • Biosimilar drug manufacturing
  • Regulatory strategy
  • Clinical trials
  • Commercial supply

Websites

  • polpharmabiologics.comPolpharma Biologics | global biosimilar developer and manufacturer
    WebflowLinkedIn AdsCloudflare

Job offers

The company has its own careers page: polpharmabiologics.com/careers.

Authorized Representatives

Adriana Maria Kiędzierska-Mencfeld age 45 – President of the Management Board
Karolina Alicja Topczewska age 49 – Management Board Member
Andrzej Uzdrowski age 44 – Management Board Member
Monika Głowacka-Różańska age 46 – Management Board Member
Justyna Tyborowska age 56 – Management Board Member

Manner of representation

If the management board is a one-person management board, the sole member of the management board is authorized to submit declarations of will on behalf of the company. If the management board is a multi-member management board, joint action by two members of the management board is required to submit declarations of will on behalf of the company.

Supervisory board

Michel Martinus Cup – Supervisory Board Member
Jakub Walkowiak age 38 – Supervisory Board Member
Konstantin Theodor Matentzoglu – Supervisory Board Member

Ownership

Owner
Polpharma Biologics Group B.v.

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2019-01-09.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Oct 1, 2026Call to creditors
Apr 29, 2026Call to creditors

Public aid

10 public aid cases recorded, with a total value of $41,268,401.

PurposeGross amount
Aid for research and development projects: experimental development
–
Aid for research and development projects: experimental development
–
Aid for research and development projects: industrial research
–

European Funds

8 projects co-financed from European Funds recorded, with total EU co-financing of $57,379,029.

ProjectEU co-financing
Strategic strengthening of the EU in the field of biological medicines through the development of a modern medicinal substance production centre
$4.6M
Development of a new, efficient process for producing a biosimilar monoclonal antibody used to treat autoimmune diseases
$5.2M
Development of a method for producing and characterising an enzyme of strategic importance for pharmaceutical production
$4M

Regulatory authorisations

AuthorityTypeStatus
Integrated permit Active
Waste generation Active

Competitors

Name
Adamed Pharma S.A.
Teva Operations Poland sp. z o.o.
Fresenius Kabi Polska sp. z o.o.
Bristol-Myers Squibb Polska sp. z o.o.
Accord Healthcare Polska sp. z o.o.
Amgen sp. z o.o.
Delpharm Poznań S.A.
Tarchomińskie Zakłady Farmaceutyczne Polfa S.A.
Przedsiębiorstwo Farmaceutyczne Lek-Am sp. z o.o.
Sandoz Polska sp. z o.o.

Change history

DateEvent
2026-09-24Share capital reduction
2026-04-17PKD change
2025-12-03Share capital reduction
2025-09-26Share capital increase
2025-07-16Share capital increase

FAQ

Last updated: 2026-09-24